Issued 2026-08-13 at $25.58 · now $25.65 (2026-08-13, +0.3% since)
Based on its own history, a month from the 2026-08-13 close, TNGX has typically landed between $17.53 and $38.45 — a range of −31.5% to +50.3% from the issuance price $25.58.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,470 overlapping 1 month windows · 2020-09-03 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($25.58) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where TNGX has typically landed a month from the 2026-08-13 close of $25.58 — the range is history, not a prediction.
- now $25.65 (+0.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $25.21 (-1.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $21.14–$29.28
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $17.53–$38.45
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-10-09 | −58.3% | −58.3% | +10.0% |
| 2024-10-10 | −55.0% | −56.8% | +13.9% |
| 2024-10-08 | −53.0% | −53.0% | +8.3% |
| 3 best | |||
| 2025-05-09 | +292.1% | +0.0% | +292.1% |
| 2025-05-08 | +278.2% | +0.0% | +287.3% |
| 2025-05-07 | +270.4% | −4.3% | +270.4% |
1,470 overlapping windows · 2020-09-03 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors (source, as of 2026-08-14)
- 2027-03-31 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.